Business Description
SynAct Pharma AB
ISIN : SE0008241491
Compare
Compare
Traded in other countries / regions
SYNACT.Sweden8F8.Germany IPO Date
2021-05-04Description
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 97.95 | |||||
| Equity-to-Asset | 0.77 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -48.7 | |||||
| 3-Year EPS without NRI Growth Rate | -78.9 | |||||
| 3-Year FCF Growth Rate | -27.8 | |||||
| 3-Year Book Growth Rate | 97.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.53 | |||||
| 9-Day RSI | 57.77 | |||||
| 14-Day RSI | 54.25 | |||||
| 6-1 Month Momentum % | -4.09 | |||||
| 12-1 Month Momentum % | -90.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.01 | |||||
| Quick Ratio | 3.01 | |||||
| Cash Ratio | 2.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.2 | |||||
| Shareholder Yield % | 0.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -105.49 | |||||
| ROA % | -85.23 | |||||
| ROIC % | -77.27 | |||||
| ROC (Joel Greenblatt) % | -4890.54 | |||||
| ROCE % | -98.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.49 | |||||
| Price-to-Tangible-Book | 10.09 | |||||
| EV-to-EBIT | -1.05 | |||||
| EV-to-EBITDA | -1.05 | |||||
| EV-to-FCF | -2.35 | |||||
| Price-to-Net-Current-Asset-Value | 12.11 | |||||
| Price-to-Net-Cash | 20.18 | |||||
| Earnings Yield (Greenblatt) % | -94.95 | |||||
| FCF Yield % | -33.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SynAct Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.584 | ||
| Beta | 1.55 | ||
| Volatility % | 135.31 | ||
| 14-Day RSI | 54.25 | ||
| 14-Day ATR (€) | 0.028836 | ||
| 20-Day SMA (€) | 0.581475 | ||
| 12-1 Month Momentum % | -90.92 | ||
| 52-Week Range (€) | 0.534 - 9.87 | ||
| Shares Outstanding (Mil) | 41.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SynAct Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SynAct Pharma AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
SynAct Pharma AB Frequently Asked Questions
What is SynAct Pharma AB(FRA:8F8)'s stock price today?
The current price of FRA:8F8 is €0.61. The 52 week high of FRA:8F8 is €9.87 and 52 week low is €0.53.
When is next earnings date of SynAct Pharma AB(FRA:8F8)?
The next earnings date of SynAct Pharma AB(FRA:8F8) is 2024-05-31.
Does SynAct Pharma AB(FRA:8F8) pay dividends? If so, how much?
SynAct Pharma AB(FRA:8F8) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers